MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy

Neurology: Neuroimmunology and NeuroInflammation

Volumn 4, Issue 2, 2017, Pages

  Ogawa, Ryo ^a   Nakashima, Ichiro ^a   Takahashi, Toshiyuki ^a,b   Kaneko, Kimihiko ^a   Akaishi, Tetsuya ^a   Takai, Yoshiki ^a   Sato, Douglas Kazutoshi ^a,c   Nishiyama, Shuhei ^a   Misu, Tatsuro ^a   Kuroda, Hiroshi ^a   Aoki, Masashi ^a   Fujihara, Kazuo ^a,d,e  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yonezawa National Hospital   (Japan)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e Southern Tohoku General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; ADULT; ANTIBODY SCREENING; ARTICLE; AUTOIMMUNE DISEASE; BENIGN UNILATERAL CEREBRAL CORTICAL ENCEPHALITIS; BRAIN DAMAGE; CASE REPORT; CELL ASSAY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONSCIOUSNESS DISORDER; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; DRUG RESPONSE; ENCEPHALITIS; EPILEPSY; GENERALIZED EPILEPSY; HUMAN; HUMAN CELL; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLEOCYTOSIS; POLYMORPHONUCLEAR CELL; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SWELLING; YOUNG ADULT;

EID: 85018237870     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000322     Document Type: Article

References (40)

1. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999;72:1-9.
2. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013;9:455-461.
3. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016;15:307-324.
4. Merkler D, Schmelting B, Czeh B, Fuchs E, Stadelmann C, Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 2006; 12:369-374.
5. Stassart RM, Helms G, Garea-Rodriguez E, et al. A new targeted model of experimental autoimmune encephalomyelitis in the common marmoset. Brain Pathol 2016; 26:452-464.
6. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:19057-19062.
7. Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011;17:297-302.
8. Waters P, Woodhall M, O'Connor KC, et al. MOG cellbased assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89. doi: 10.1212/NXI.0000000000000089.
9. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014;71:276-283.
10. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
11. Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013;19:1052-1059.
12. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients: Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280.
13. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015; 2:e163. doi: 10.1212/NXI.0000000000000163.
14. Cianfoni A, Caulo M, Cerase A, et al. Seizure-induced brain lesions: A wide spectrum of variably reversible MRI abnormalities. Eur J Radiol 2013;82:1964-1972.
15. Chatzikonstantinou A, Gass A, Forster A, Hennerici MG, Szabo K. Features of acute DWI abnormalities related to status epilepticus. Epilepsy Res 2011;97:45-51.
16. Milligan TA, Zamani A, Bromfield E. Frequency and patterns of MRI abnormalities due to status epilepticus. Seizure 2009;18:104-108.
17. Varadkar S, Bien CG, Kruse CA, et al. Rasmussen's encephalitis: Clinical features, pathobiology, and treatment advances. Lancet Neurol 2014;13:195-205.
18. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404.
19. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;12:157-165.
20. Huda S, Wong SH, Pettingill P, O'Connell D, Vincent A, Steiger M. An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J Neurol 2015;262:418-424.
21. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470-478.
22. Yoneda M, Fujii A, Ito A, Yokoyama H, Nakagawa H, Kuriyama M. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol 2007;185: 195-200.
23. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
24. Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2015;2:e110. doi: 10.1212/NXI.0000000000000110.
25. Maeda M, Yagishita A, Yamamoto T, Sakuma H, Takeda K. Abnormal hyperintensity within the subarachnoid space evaluated by fluid-attenuated inversion-recovery MR imaging: A spectrum of central nervous system diseases. Eur Radiol 2003;13(suppl 4):L192-L201.
26. Numa S, Kasai T, Kondo T, et al. An adult case of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated multiphasic acute disseminated encephalomyelitis at 33-year intervals. Intern Med 2016;55:699-702.
27. O'Connor KC, McLaughlin KA, De Jager PL, et al. Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211-217.
28. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833-842.
29. Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013;19:941-946.
30. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62. doi: 10.1212/NXI.0000000000000062.
31. Dale RC, Tantsis EM, Merheb V, et al. Antibodies toMOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014;1: E12. doi: 10.1212/NXI.0000000000000012.
32. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014;2:35.
33. Konig FB, Wildemann B, Nessler S, et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008;65:1527-1532.
34. Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015;2:295-301.
35. Lucchinetti C, BruckW, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
36. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3: E257. doi: 10.1212/NXI.0000000000000257.
37. Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 2016;87:1257-1259.
38. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411-428.
39. Nishiyama S, Ito T,Misu T, et al. A case ofNMOseropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009;72:1960-1961.
40. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265-272.